|
Jun 18
|
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
|
|
Jun 18
|
Intra-Cellular depression drug succeeds in second late-stage study
|
|
Jun 10
|
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
|
|
May 9
|
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its First-Quarter Earnings: Here's What Analysts Think
|
|
May 8
|
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
|
|
May 8
|
Intra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
|
|
May 7
|
Intra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA Sales
|
|
May 7
|
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
|
|
May 1
|
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
|
|
Apr 30
|
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
|
|
Apr 25
|
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 24
|
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Apr 24
|
3 Biotech Stocks With Skyrocketing Potential: April 2024
|
|
Apr 22
|
10 Best Performing Biotech ETFs in 2024
|
|
Apr 18
|
Intra-Cellular Therapies Prices Public Offering of Common Stock
|
|
Apr 17
|
Biotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point
|
|
Apr 17
|
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
|
|
Apr 17
|
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
|